LUNG CANCER

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy elicited robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

First-in-human results of a phase 1 trial (NCT03319940) evaluating AMG 757 in patients with small cell lung cancer revealed early signals of efficacy and a favorable safety profile in findings presented at the European Lung Cancer Virtual Congress 2021.

Results from an observational, multicenter study that evaluated osimertinib reveal encouraging real-world efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer.

The time to initiate durvalumab treatment following chemoradiation was delayed in the real-world setting trial PACIFIC-R (NCT02125461) compared with the earlier phase 3 PACIFIC trial.

Updated findings from the early-stage KRYSTAL-1 study showed that treatment with adagrasib resulted in durable responses, broad disease control, and provided extensive predicted coverage throughout the dosing interval in patients with KRAS G12Cmutant advanced non–small cell lung cancer.

Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, discussed the case of a 59-year-old patients with non–small cell lung cancer.

Tina Cascone, MD, PhD, discusses the basis for conducting the phase 3 IMpower010 study.

Jamie E. Chaft, MD, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer.

Data presented at the 2021 virtual ASCO Annual Meeting showed the benefits of adding nivolumab to chemotherapy treatment compared to chemotherapy alone, in patients with resectable non-small cell lung cancer.

New data from the phase 3 IMPACT trial shows the advantages and shortcomings of gefitinib in patients with EGFR-mutant non-small cell lung cancer.

Overall survival was not improved with alectinib in patients with treatment-naïve, advanced ALK-positive non-small cell lung cancer, compared to crizotinib.

Consistent efficacy was seen with selpercatinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Updated results from the phase 2 CodeBreaK100 trial were presented by Ferdinandos Skoulidis, MD, PhD during the 2021 ASCO Annual Meeting.

Jorge Nieva, MD, discusses the backgroup to the IMpower010 study, the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Continued efficacy is seen with nivolumab and ipilimumab plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer.

Sustained overall survival and progression-free survival benefits was confirmed following long-term treatment with durvalumab following chemoradation in patients with unresectable stage 3 non-small cell lung cancer whose disease had not progressed after platinum-based concurrent chemoradiotherapy.

After 4 years of treatment with the combination of nivolumab and ipilimumab, the therapy showed durable, long-term overall survival benefit compared with chemotherapy in patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Mobocertinib, elicited rapid, deep, and durable responses and demonstrated a tolerable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in a phase 1/2 study.

According to results from the phase 1/2 and phase 2 ALTA trials, brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.

Pembrolizumab plus concurrent chemoradiation therapy continues to demonstrate promising antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.

Sugemalimab, an anti-PD-L1 antibody, helps to prolong progression-free survival in patients with locally advanced, unrespectable stage III non–small cell lung cancer without disease progression after either concurrent or sequential chemotherapy.

Jared Weiss, MD, shares insight into current unmet needs in extensive-stage small cell lung cancer and provides advice to researchers about the importance of clinical trials studying differential treatments and biomarkers.

Expert oncologist Jared Weiss, MD, considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed small cell lung cancer.